126 related articles for article (PubMed ID: 11342370)
1. Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia.
Kamihira S; Yamada Y
Leuk Lymphoma; 2001 Mar; 41(1-2):169-76. PubMed ID: 11342370
[TBL] [Abstract][Full Text] [Related]
2. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis.
Kamihira S; Yamada Y; Tomonaga M; Sugahara K; Tsuruda K
Br J Haematol; 1999 Dec; 107(4):851-60. PubMed ID: 10606894
[TBL] [Abstract][Full Text] [Related]
3. Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines.
Sugahara K; Yamada Y; Hiragata Y; Matsuo Y; Tsuruda K; Tomonaga M; Maeda T; Atogami S; Tsukasaki K; Kamihira S
Int J Cancer; 1997 Jul; 72(1):128-32. PubMed ID: 9212233
[TBL] [Abstract][Full Text] [Related]
4. Soluble Fas/Apo-1 splicing variants and apoptosis.
Cascino I; Papoff G; Eramo A; Ruberti G
Front Biosci; 1996 Jan; 1():d12-8. PubMed ID: 9159204
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases.
Kamihira S; Yamada Y; Hiragata Y; Yamaguchi T; Izumikawa K; Matsuo Y; Sugahara K; Tsuruta K; Atogami S; Tsukasaki K; Maeda T; Tomonaga M
Intern Med; 1997 Mar; 36(3):166-70. PubMed ID: 9144006
[TBL] [Abstract][Full Text] [Related]
6. Clinical and oncological significance of aberrant Fas (APO-1/CD95) isoform expression in adult T-cell leukemia.
Kamihira S; Yamada Y; Maeda T
Indian J Clin Biochem; 2000 Aug; 15(Suppl 1):101-9. PubMed ID: 23105273
[TBL] [Abstract][Full Text] [Related]
7. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells.
Tamiya S; Etoh K; Suzushima H; Takatsuki K; Matsuoka M
Blood; 1998 May; 91(10):3935-42. PubMed ID: 9573032
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis.
Kamihira S; Yamada Y; Hirakata Y; Tomonaga M; Sugahara K; Hayashi T; Dateki N; Harasawa H; Nakayama K
Br J Haematol; 2001 Jul; 114(1):63-9. PubMed ID: 11472346
[TBL] [Abstract][Full Text] [Related]
9. Fas gene mutation in the progression of adult T cell leukemia.
Maeda T; Yamada Y; Moriuchi R; Sugahara K; Tsuruda K; Joh T; Atogami S; Tsukasaki K; Tomonaga M; Kamihira S
J Exp Med; 1999 Apr; 189(7):1063-71. PubMed ID: 10190897
[TBL] [Abstract][Full Text] [Related]
10. mRNA expression of variant Fas molecules in acute leukemia cells.
Inaba H; Komada Y; Li QS; Zhang XL; Tanaka S; Azuma E; Yamamoto H; Sakurai M
Am J Hematol; 1999 Nov; 62(3):150-8. PubMed ID: 10539881
[TBL] [Abstract][Full Text] [Related]
11. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease.
Silvestris F; Cafforio P; Tucci M; Del Prete A; Dammacco F
Mol Med; 2000 Jun; 6(6):509-26. PubMed ID: 10972087
[TBL] [Abstract][Full Text] [Related]
12. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
Bruserud O; Ulvestad E
Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Villunger A; Egle A; Kos M; Hartmann BL; Geley S; Kofler R; Greil R
Cancer Res; 1997 Aug; 57(16):3331-4. PubMed ID: 9269989
[TBL] [Abstract][Full Text] [Related]
14. Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease.
Silvestris F; Williams RC; Calvani N; Grinello D; Tucci M; Cafforio P; Dammacco F
Clin Exp Med; 2002 May; 2(1):13-27. PubMed ID: 12049185
[TBL] [Abstract][Full Text] [Related]
15. U2AF - Hypoxia-induced fas alternative splicing regulator.
Vilys L; Peciuliene I; Jakubauskiene E; Zinkeviciute R; Makino Y; Kanopka A
Exp Cell Res; 2021 Feb; 399(1):112444. PubMed ID: 33347855
[TBL] [Abstract][Full Text] [Related]
16. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells.
Karawajew L; Wuchter C; Ruppert V; Drexler H; Gruss HJ; Dörken B; Ludwig WD
Leukemia; 1997 Aug; 11(8):1245-52. PubMed ID: 9264377
[TBL] [Abstract][Full Text] [Related]
17. Lack of Fas (APO-1/CD95) gene structural alterations or transcript variant ratio changes in breast cancer.
Puiu L; Petrakou E; Apostolidou A; Athanassiadou A; Psiouri L; Papachatzopoulou A; Gorgoulis VG; Kotsinas A; Tzoracoeleftherakis E; Maniatis GM; Voutsinas G
Cancer Lett; 2003 May; 194(1):91-7. PubMed ID: 12706862
[TBL] [Abstract][Full Text] [Related]
18. [Fas antigen (CD95) expressions and apoptosis of neoplastic cells from various lymphoid malignancies including adult T-cell leukemia/lymphoma].
Sasao T; Yoshida M; Ichikawa Y
Nihon Rinsho; 1996 Jul; 54(7):1986-91. PubMed ID: 8741700
[TBL] [Abstract][Full Text] [Related]
19. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines.
Fellenberg J; Mau H; Scheuerpflug C; Ewerbeck V; Debatin KM
Int J Cancer; 1997 Jul; 72(3):536-42. PubMed ID: 9247301
[TBL] [Abstract][Full Text] [Related]
20. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells.
Friesen C; Fulda S; Debatin KM
Leukemia; 1997 Nov; 11(11):1833-41. PubMed ID: 9369415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
